Ignite Creation Date:
2025-12-25 @ 12:12 AM
Ignite Modification Date:
2026-01-25 @ 4:22 PM
Study NCT ID:
NCT04394858
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-12-24
First Post:
2020-05-19
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer
Sponsor:
National Cancer Institute (NCI)
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Advanced Adrenal Gland Pheochromocytoma | View |
| None | Advanced Paraganglioma | View |
| None | Metastatic Adrenal Gland Pheochromocytoma | View |
| None | Metastatic Paraganglioma | View |
| None | Stage III Adrenal Gland Pheochromocytoma and Sympathetic Paraganglioma AJCC v8 | View |
| None | Stage IV Adrenal Gland Pheochromocytoma and Sympathetic Paraganglioma AJCC v8 | View |
| None | Unresectable Adrenal Gland Pheochromocytoma | View |
| None | Unresectable Paraganglioma | View |
Keywords: